What is KYMR's current stock price?

KYMR (Kymera Therapeutics, Inc.) is currently trading at $78.89 with a market cap of $6.49B.

What sector is Kymera Therapeutics, Inc. in?

Kymera Therapeutics, Inc. (KYMR) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is KYMR a good stock to buy?

Analysts have a Buy consensus on KYMR with a price target of $118.06. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

KYMR Kymera Therapeutics, Inc.

Healthcare

$78.89-2.13%ClosedMarket Cap: $6.49B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.00

P/S

126.09

EV/EBITDA

-21.00

DCF Value

$0.17

FCF Yield

-3.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

100.0%

Operating Margin

-697.8%

Net Margin

-612.2%

ROE

-25.0%

ROA

-18.9%

ROIC

-22.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$34.4M	$-69.2M	$—
Q4 null	$2.9M	$-87.0M	$—
FY null	$39.2M	$-311.4M	$—
Q3 null	$2.8M	$-82.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$118.06

Target (Median)

$118.50

Target Range

$90.00 - $138.00

5 Strong Buy18 Buy1 Hold0 Sell0 Strong Sell

UBSBuy

2026-03-03

Stephens & Co.Overweight

2026-03-02

CitigroupBuy

2026-03-02

BTIGBuy

2026-02-26

Piper SandlerOverweight

2026-02-26

Trading Activity

Insider Trades

View All

Jacobs Bruce N.officer: Chief Financial Officer

SellTue May 19

Esposito Pameladirector

SellTue May 19

Ridloff Elenadirector

SellMon May 11

Ridloff Elenadirector

SellMon May 11

Mainolfi Nellodirector, officer: Chief Executive Officer

SellWed Apr 29

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.06

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Peers